

1631

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 26 2003

Applicant(s): Stephen Horrigan

Serial No: 09/964,824

Art Unit: 1631

TECH CENTER 1600/2900

Filed: 27 September 2001

Examiner: C.L Smith

Title: CANCER GENE DETERMINATION AND THERAPEUTIC
SCREENING USING SIGNATURE GENE SETS

Docket No: 689290-73

18 November 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

Sir: Applicant herewith files the following:

1. Information Disclosure Statement;
2. Form 1449 plus copies of cited references; and
3. Return Postcard

No fee is believed due in filing this paper. The Commissioner is requested to charge any fees due, or credit any refunds, to Deposit Acc't No. 03-0678.

Serial No.: 09/964,824
Filed: 27 September 2001

FIRST CLASS CERTIFICATE

I hereby certify that this
correspondence is being deposited
today with the U.S. Postal Service as
First Class Mail in an envelope
addressed to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450


Alan J. Grant 11/18/03
Alan J. Grant, Esq. Date

Respectfully submitted,

Alan J. Grant

Alan J. Grant, Esq.
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, NJ 07068
Phone: 973-994-1700
Fax: 973-994-1744



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 26 2003

TECH CENTER 1600/2900

Applicant(s): Stephen K. Horrigan
Serial No: 09/964,824 Art Unit: 1631
Filed: 27 September 2001 Examiner: C. L. Smith
Title: CANCER GENE DETERMINATION AND THERAPEUTIC
SCREENING USING SIGNATURE GENE SETS
Docket No: 689290-73

18 November 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

___§1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.
No fee or statement is required.

___§1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

- ☐ The statement as specified in 37 CFR §1.97(e) set out below; OR
- ☐ The fee of \$ 180.00 under 37 CFR §1.17(p).

☐ §1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

☒ §1.97(e) The undersigned Attorney hereby states that:

☐ each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;
or

☒ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.


Serial No: 09/964,824
Filed: 27 September 2001

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.


FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**


Alan J. Grant, Esq. 11/18/03
Date

Respectfully submitted,




Alan J. Grant, Esq.
Reg. No. 33,389

CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, NJ 07068
Phone: 973-994-1700
Fax: 973-994-1744

Form PTO-1449

INFORMATION DISCLOSURE STATEMENT



Atty. Docket:

689290-73

Serial No.

09/964,824

Applicant: Stephen Horrigan

Filing Date: 27 September 2001

Group: 1631

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing Date
AA	6,100,031	8 August 2000	Shyjan et al			
BB						
CC						

RECEIVED

NOV 26 2003

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Sub-Class	Translation
DD	WO 97/33551	September 1997	PCT			<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
EE						<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

TECH CENTER 1600/2900

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

FF	Da-Xiang et al (J. Fourth Milit. Med. Univ.) Vol. 19 (6):601-605 (1998)
GG	
HH	
II	
JJ	
KK	
LL	
MM	
NN	
OO	

Examiner:

Date Considered:

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.